<DOC>
	<DOCNO>NCT01688089</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability escalate dos ODM-103 give healthy male volunteer .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics ODM-103 Healthy Volunteers</brief_title>
	<detailed_description>The study divide two part . Part one crossover study healthy volunteer receive two dos ODM-103 one dose placebo . Part II study multiple ascend dose parallel group study healthy volunteer receive ODM-103 three time daily seven day . Healthy volunteer take part Part II study also receive levo/carbidopa entacapone four time daily day 1 levo/carbidopa addition ODM-103 day 9 . The study also look pharmacokinetic ( body handle drug ) pharmacodynamics ( drug affect body ) ODM-103 .</detailed_description>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Male subject age 18 45 year BMI 1830 kg/m2 Weight 5590kg Written informed consent Good General Health Vulnerable subject Veins unsuitable repeat venipuncture Evidence clinically significant cardiovascular , renal , hepatic , hematological , Gi , pulmonary , metabolicendocrine , neurological , urogenital psychiatric disorder History positive test drug abuse Any condition require regular concomitant medication Blood donation significant loss blood within 3 month prior screen Abnormal 12 lead ECG find clinical relevance Heart rate ( HR ) &lt; 50bpm &gt; 90bpm 10 minute supine position Systolic blood pressure &lt; 90mmHg &gt; 140mmHg 10 minute supine position Diastolic blood pressure &lt; 50mmHg &gt; 90mmHg 10 minute supine position Abnormal 24 hour Holter record clinical relevance screen Any abnormal laboratory value , vital sign physical examination cause health risk volunteer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>volunteer</keyword>
	<keyword>study</keyword>
</DOC>